Atea’s woes grow while other Covid readouts approach
Big upcoming events include data from a trial of Pfizer’s oral antiviral Paxlovid in patients at risk of severe illness.
No let-up in Covid-19 vaccine trials
A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.
Covid-19 vaccine leaders make hay while Novavax flounders
Instead of long-awaited phase 3 data Novavax’s first-quarter presentation reveals a Covid-19 vaccine manufacturing snafu.
Valneva joins the phase 3 Covid-19 vaccine club
Meanwhile, Ocugen hopes that Covaxin's India data will be enough for US approval.
Inovio’s reinvention falls flat
The company’s claims of a win with its cervical precancer therapy candidate look questionable.
Clinical developments over the Christmas period 2020
Trial results in Covid-19 and cancer emerge, but little promise is seen.